media – Page 35 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

How Platforms Are Reshaping Buyer–Supplier Collaboration

As the global pharmaceutical market continues to expand and cross-border e-commerce accelerates, efficiency has become the new priority in international trade. This article leverages market data and practical insights from Drugdu.com to examine how this shift is transforming the way buyers and suppliers collaborate. I. Global Trends: Pharmaceutical Trade on the Rise Sustained Market Growth: The global pharmaceutical market was valued at USD 1.65 trillion in 2024 and is projected to reach USD 2.35 trillion by 2030, growing at a CAGR of 6.1%. (Source: Grand View Research) Export Volume and Structural Shifts: In 2024, the value of global pharmaceutical exports reached approximately USD 1.8 trillion, with vaccines and oncology drugs accounting for 32% and 26%, respectively. (Source: Grand View Research) Europe also recorded significant growth, with pharmaceutical exports rising by 13.5% year-on-year in 2024 and its trade surplus expanding to EUR 194 billion. (Source: European Commission) II. The Rise of Cross-Border ...
- Source: drugdu
- 97
- September 2, 2025
HBME Wuhan

Organiser: China Council for the Promotion of International Trade Hubei Sub-Council, China Chamber of International Commerce Hubei Chamber of Commerce Time：March 13 – March 15, 2026 address：No. 696 Jiefang Avenue, Jianghan District, Wuhan City, Hubei Province Exhibition hall：Wuhan International Convention and Exhibition Center Product range: Diagnostic Equipment: Ultrasound diagnostic equipment, X-ray imaging diagnostic equipment, electrocardiogram (ECG) and encephalogram (EEG) monitoring equipment, image processing systems, scanning equipment, biochemical testing equipment, functional examination equipment, pathological diagnostic equipment, endoscopic examination equipment, patient monitors, optical instruments, and examination and diagnostic equipment for neurology, orthopedics, otolaryngology, ophthalmology, etc. Therapeutic Equipment: Surgical equipment for internal and external medicine, radiotherapy equipment, nuclear medicine treatment equipment, dialysis treatment equipment, radiofrequency treatment equipment, cryotherapy equipment, laser equipment, rehabilitation and physiotherapy equipment, emergency equipment, anesthesia and analgesia equipment, operating room equipment, surgical lights, operating tables, high-frequency electrosurgical units, etc., as well as dialysis treatment equipment, emergency equipment, anesthesia and ...
- Source: drugdu
- 206
- September 2, 2025
Babies fed blueberries show fewer allergy symptoms and boosted immune balance

In a recent study published in the journal Nutrients, researchers examined the impact of blueberry intake in early life on allergy-related symptoms, gut microbiota, and immune biomarkers. The complementary feeding period represents a critical time frame for shaping infant immune development, diet, and gut microbiota. Current recommendations suggest introducing a range of plant-based foods from six months of age, in conjunction with continued breastfeeding. Growing evidence supports a role for blueberries in the microbiota-inflammation-immunity axis and gut microbial homeostasis. The first year of life is a critical window for establishing immune competence and preventing allergic diseases. Dietary exposures during this period can influence the induction of immune tolerance, epigenetic programming, and gut microbial succession. Suboptimal or aberrant microbial colonization has been linked to increased gut permeability, impaired innate immune responses, and low-grade inflammation, all of which are associated with a higher risk of diseases in later life. About the study ...
- Source: drugdu
- 76
- September 1, 2025
First ESC statement on mental health and heart disease promotes integrated care

A new ESC Clinical Consensus Statement is calling for greater awareness of the multidirectional relationship between mental health conditions and cardiovascular disease to improve patient health. The first ever ESC Clinical Consensus Statement to be developed on this topic was published today at ESC Congress 2025. The Consensus Statement recommends that mental health symptoms are systematically screened for during cardiovascular care, and cardiovascular risk is routinely assessed for those being treated for mental health conditions. While poor mental health can be a contributory factor to cardiovascular disease, people living with cardiovascular disease are also at greater risk of poor mental health. Patients experiencing both cardiovascular disease and a mental health condition have worse health outcomes. The Consensus Statement has been produced by an international panel of experts that includes co-Chairpersons Professor Héctor Bueno, from the National Cardiovascular Research Center (CNIC) and the Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, ...
- Source: drugdu
- 83
- September 1, 2025
Another Phase III clinical study of Tetasip is successful

On August 27, Rongchang Biopharma announced that its independently developed world’s first BLyS/APRIL dual-target fusion protein innovative drug Taitasip (trade name: Tai Ai®) for the treatment of primary immunoglobulin A (IgA) nephropathy reached the primary study endpoint of Phase A in the domestic Phase III clinical study. Study results showed that compared with the placebo group, patients in the tetasip group experienced a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at week 39 of treatment (P<0.0001), demonstrating good tolerability and safety. Rongchang Biopharma stated that it will submit a marketing application to the National Medical Products Administration (NMPA) as soon as possible, and detailed data will be presented at a major international academic conference. This multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial enrolled 318 adult patients with IgA nephropathy receiving standard treatment. Tetasipir was administered at a dose of 240 mg subcutaneously once weekly. The study aimed to ...
- Source: drugdu
- 87
- September 1, 2025
A world first! Sino Biopharmaceutical’s oral targeted drug, Sanhetu, for advanced non-small cell lung cancer with HER2 mutations has been approved

On August 29, Boehringer Ingelheim and Sino Biopharmaceutical (01177.HK) jointly announced that their jointly promoted drug, Zongertinib (Chinese generic name: Zongertinib tablets, English generic name: zongertinib), has been officially approved by the China National Medical Products Administration for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating HER2 (ERBB2) mutations and have received at least one previous systemic therapy. Sanhetu® is the world’s first and currently only approved oral HER2 tyrosine kinase inhibitor. Its conditional approval in China is based on positive results from the Beamion-LUNG 1 study, which evaluated the efficacy and safety of zonectinib in patients with advanced non-small cell lung cancer (NSCLC) harboring a HER2 (ERBB2) mutation. Data from cohort 1 (N=75) of previously treated patients demonstrated an objective response rate (ORR) of 71% (95% CI: 60-80), including 7% complete responses, and a disease control rate (DCR) ...
- Source: drugdu
- 73
- September 1, 2025
Scientists develop new mRNA vaccine platform that can significantly enhance the body’s immune response

Yale University researchers have developed a novel mRNA vaccine platform designed to significantly enhance immune responses, improve the effectiveness of mRNA vaccines, and expand their potential for preventing and treating a variety of diseases. The study, published in the latest issue of Nature Biomedical Engineering, demonstrates that this vaccine platform technology could make future mRNA vaccines more reliable and effective. mRNA vaccines have become increasingly popular in recent years. Their principle is to provide genetic instructions to human cells, enabling them to produce specific viral proteins on their own, thereby triggering an immune response. However, this technology has limited effectiveness in treating certain diseases, prompting researchers to continuously optimize its delivery system. Researchers have found that the key to the effectiveness of mRNA vaccines lies in whether the antigens can be effectively recognized by the immune system. Antigens must appear on the cell surface to be detected by the immune ...
- Source: drugdu
- 93
- September 1, 2025
Difluprednate API Approved, Strengthening Advantages of Integrated API and Pharmaceutical Preparations

August 29, Jinyao Pharmaceutical(600488) issued an announcement. Recently, the company received the ” Chemical Raw Materials ” certificate for difluprednate approved by the State Food and Drug Administration.Approval of the Drug Marketing Application. It is understood that difluprednate is a topical corticosteroid that can inhibit inflammatory responses caused by various irritants. Currently, the main dosage form on the market is eye drops, primarily used to treat inflammation and pain associated with eye surgery. According to statistics from the IQVIA database, the global sales of difluprednate preparations (including single and compound preparations) in 2023 and 2024 will be US$49 million and US$41 million, respectively. The announcement indicates that the company submitted its registration application for difluprednate API to the National Medical Products Administration (NMPA) in August 2020 and was accepted. From June to October 2022, the company completed the submission of supplementary documentation as required by the notice and recently received ...
- Source: drugdu
- 71
- September 1, 2025
【EXPERT Q&A】In what aspects is trimethylolpropane used?

Drugdu.com expert’s response: Trimethylolpropane (TMP), as a critical fine chemical product, demonstrates extensive application value across multiple industrial sectors. Its core uses can be summarized as follows: I. Resin Synthesis: A Key Raw Material for Enhancing Material Performance Alkyd and Polyurethane Resins: TMP serves as a cornerstone raw material for synthesizing alkyd and polyurethane resins. Its three hydroxymethyl groups enable cross-linking reactions with organic acids or diisocyanates, significantly improving resin hardness, abrasion resistance, chemical resistance, and weatherability. For example, in automotive coatings, TMP-containing resins enhance UV and acid rain resistance, extending vehicle lifespan. Unsaturated Polyester and Epoxy Resins: As a chain extender or cross-linker, TMP increases polymer molecular weight, enhancing mechanical properties (e.g., tensile strength, impact resistance) and thermal stability. It is widely applied in aerospace, electronics, and other high-end fields. Coatings and Inks: Optimizing Performance and Processes Coatings Industry: TMP is a vital component in high-performance coatings, improving drying ...
- Source: drugdu
- 183
- September 1, 2025
Healthy gut bacteria capsules show long-term benefits for obese teenagers

Can a capsule of healthy gut bugs change the future of obesity treatment? New findings from the University of Auckland’s Liggins Institute suggest it might. Eight years ago, 87 obese adolescents took part in a groundbreaking study to see whether fecal transfer (taking ‘good’ gut bacteria from healthy donors and giving them in capsule form to people with a less healthy microbiome) would make a difference to their health and weight. Four years later, a follow-up study, published this week in the world-leading scientific journal Nature Communications , suggests some significant health benefits from that single gut bugs transfer. In particular, the original overweight teens who received the transfer had reduced risk for a bunch of metabolic changes which can lead to heart disease, stroke and diabetes, compared with the participants who received the placebo. Obesity is a significant health problem in New Zealand and elsewhere in the world. In ...
- Source: drugdu
- 102
- August 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.